老年非小细胞肺癌患者紫杉烷类药物引起的发热性中性粒细胞减少的一级预防指征。
Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer.
机构信息
Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
出版信息
Cancer Invest. 2020 Aug;38(7):424-430. doi: 10.1080/07357907.2020.1793350. Epub 2020 Jul 30.
In advanced non-small cell lung cancer (NSCLC), the reported incidence of febrile neutropenia (FN) caused by docetaxel (DTX) is 10-20% in clinical trial data. However, FN incidence caused by DTX in real-world setting remains unclear. We evaluated FN incidence caused by DTX and identify risk factors of FN in real-world setting. One hundred and seventy-one NSCLC patients treated with DTX were retrospectively analyzed and 44 (26%) developed FN. Multivariate analysis identified higher age (≥65 years) and prior history of FN as independent risk factors for FN. Primary prophylaxis for FN might be recommended in elderly patients with/without prior history of FN.
在晚期非小细胞肺癌（NSCLC）中，临床试验数据报道多西他赛（DTX）引起的发热性中性粒细胞减少症（FN）发生率为 10-20%。然而，真实世界环境中 DTX 引起 FN 的发生率尚不清楚。我们评估了真实世界环境中 DTX 引起 FN 的发生率，并确定 FN 的危险因素。对 171 例接受 DTX 治疗的 NSCLC 患者进行回顾性分析，其中 44 例（26%）发生 FN。多变量分析确定年龄较高（≥65 岁）和既往 FN 病史是 FN 的独立危险因素。对于有/无既往 FN 病史的老年患者，可能需要进行 FN 的一级预防。
Zotero 插件